Kiniksa Pharmaceuticals International plc Class A Company Profile
NASDAQ: KNSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Kiniksa Pharmaceuticals International at a glance
Kiniksa Pharmaceuticals International plc Class A (NASDAQ: KNSA) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in London. Kiniksa Pharmaceuticals International is led by Mr. Sanjiv K. Patel and employs about 366 people. The company's shares have traded publicly since 2018.
At a market capitalization of $6.08 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001730430, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Kiniksa Pharmaceuticals International do?
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Business description based on the company's public filings.
Company information
- Legal name
- Kiniksa Pharmaceuticals International plc Class A
- Ticker
- NASDAQ: KNSA
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Sanjiv K. Patel
- Employees
- 366
- Headquarters
- 105 Piccadilly, London, United States
- Phone
- 44 78 1431 9100
- Website
- kiniksa.com
- IPO year
- 2018
- Market cap
- $6.08B
- SEC CIK
- 0001730430
- Latest annual report
- 10-K · Feb 24, 2026
Companies similar to Kiniksa Pharmaceuticals International
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BLTEBelite Bio Inc ADR | 152.52 | -2.28% | $6.14B | vs KNSA |
| RYTMRhythm Pharmaceuticals Inc. | 89.64 | +1.35% | $6.17B | vs KNSA |
| LGNDLigand Pharmaceuticals Incorporated | 295.00 | +0.59% | $5.88B | vs KNSA |
| ALKSAlkermes plc | 40.11 | -3.22% | $6.73B | vs KNSA |
| ERASErasca Inc. | 15.46 | +9.49% | $5.41B | vs KNSA |
| AMRXAmneal Pharmaceuticals Inc. Class A | 19.65 | 0.00% | $6.84B | vs KNSA |
| MANEVeradermics Incorporated | 126.63 | +14.13% | $5.29B | vs KNSA |
| MIRMMirum Pharmaceuticals Inc. | 81.35 | +0.88% | $5.28B | vs KNSA |